Navigation Links
ASE-EAE to issue guidelines for the echocardiographic evaluation of cancer patients
Date:10/20/2011

"Considering that the early detection of cardio toxicity is a critical issue for patients undergoing chemotherapy, the ASE and the EAE have come together to write guidelines which will highlight the technical advantages of echocardiography in identifying cardio toxicity early," explained Prof Juan Carlos Plana, Co-Director of the Cardio-oncology Center, Cleveland Clinic, from the ASE. "This would help select patients who would benefit from cardio protective regimens, so that heart failure does not become an obstacle to the oncologist during therapy, and to the patient during his/her survival."

In the last decade cancer therapy has had an enormous progress leading to an important reduction of morbidity and mortality of several types of cancer. The therapeutic management of patients with cancer includes a combination of drugs, radiation therapy, and surgery. Several of these therapies, mainly anthracyclines, produce potential adverse cardiac reactions which can negatively impact the quality of life as well as the prognosis of oncologic patients. The new generation of targeted therapies (i.e. trastuzumab in breast cancer) has also been associated with unexpected unfavorable side effects on myocardial function. Currently, 17% of patients have to stop cancer therapy due to heart involvement.

"Detecting cardio toxicity is a critical issue in the clinical setting, in order to appropriately modulate and, hopefully, not interrupt cancer therapy. The traditional screening of patients with cancer includes a cardiac examination, and both an electrocardiogram (EKG) and a 2D echocardiogram with Doppler at baseline. The monitoring of cardiovascular toxicity might be more accurate using endomyocardial biopsy. However, the test is highly invasive and not free from complications," stated Dr Maurizio Galderisi, from the Federico II University in Naples, Italy and chairperson of the EAE task force.

Echocardiography has emerged as the modality of choice for noninvasive evaluation of cardiac disease in the cancer patient. This tool is essential for the evaluation of left ventricular systolic and diastolic dysfunction, pericardial and valvular heart disease. However, echocardiograms are only routinely performed at the beginning of cancer therapy, in order to document a normal left ventricular systolic function. Further echocardiographic follow up during cancer therapy is performed only as a consequence of the onset of cardiac symptoms and/or signs, in particular following the administration of recognized cardiotoxic drugs or radiation therapy.

Dr Rosa Sicari, FESC, from the CNR Institute of Clinical Physiology, Pisa, Italy and chairperson of the EAE Scientific Committee adds that "the assessment of cardiac toxicity remains a critical issue in oncology. Ejection fraction, the time honored parameter of function is not useful for the detection of early and subtle forms of cardiac dysfunction. New tools are needed and the evidence should be built in the near future with appropriately designed studies and with the common efforts of oncologists, cardiologists and pharmacologists. This document is not meant to fill the gap of knowledge but to provide the state of the art of ultrasound in this field and indicate new research pathways."

On these premises, the upcoming joint recommendations of the American Society of Echocardiography and European Association of Echocardiography will present the need and clinical usefulness of serial echocardiographic evaluations, and the potential impact of more advanced ultrasound technologies in patients undergoing cancer therapy.


'/>"/>

Contact: ESC Press Office
press@escardio.org
33-492-948-627
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. New Guidelines Issued for Common Tremor Disorder
2. Health groups issue proposed cervical cancer screening guidelines
3. New tool to help surgeons remove more cancer tissue during brain surgery
4. People With Mental Health Issues More Likely to Be Uninsured
5. Rebooting the system: Immune cells repair damaged lung tissues after flu infection
6. Academic issues warning on schoolboy rugby
7. FRAX calculator issued in version 3.4
8. Transformative NIH grant will support development of tissue regeneration therapeutics
9. Computer-aided design used for breast tissue reconstruction
10. New model of ALS is based on human cells from autopsied tissue
11. ACR and SBI issue statement on British Medical Journal article on effect of mammography on breast cancer death rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In Madeira ... the mainland by a single drawbridge, citizens formed an organization, Madeira Beach United, to ... traffic and change the small town center to a high rise urban environment. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... Women’s athletic apparel company ... second pop-up shop for three consecutive weekends. The pop-up shop is a great ... community, a community full of women who appreciate the most premium goods and ...
(Date:5/25/2016)... ... May 26, 2016 , ... The United States Food and Drug ... in both men and women. To date, the company is the first and only ... any adult who suffers with androgenetic alopecia. , “This new level of clearance ...
(Date:5/25/2016)... ... May 25, 2016 , ... Extremity ... Tennessee locations to streamline patient check-in and post visit surveys. , “The Phreesia ... patient care. It has revolutionized the check-in process for our clinic network, providing ...
(Date:5/25/2016)... ... May 25, 2016 , ... A new update to Xsens ... all by utilizing a common Wi-Fi network and a mobile device. When paired with ... location with Wi-Fi, and use a mobile device to control the recording. , ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... PUNE, India , May 25, 2016 /PRNewswire/ ... Pipeline Review, H1 2016"market research report that provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ...
(Date:5/24/2016)... 24, 2016   ... primären Endpunkte und demonstriert Ebenbürtigkeit bei ... ‚ausgezeichneter plus guter , ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) ... positive Daten von der MORA-Studie der Phase III ...
(Date:5/24/2016)... ARANZ Medical  Ltd a specialist ... has been named the Coretex Hi-Tech Emerging Company of the ... Dr Bruce Davey , CEO of ARANZ Medical says, ... good to be recognised for the work we are doing ... in 35 countries around the world from Sub-Saharan Africa through ...
Breaking Medicine Technology: